NYSE:DGXHealthcare
Quest Diagnostics (DGX) Expands Oncology Test Access, Is The Stock Fully Valued?
Why Quest Diagnostics Stock Is Back in Focus
Quest Diagnostics (DGX) is back on investor watchlists after the company moved to integrate its Haystack MRD ctDNA and Comprehensive Genomic Profiling cancer tests directly into Flatiron Health’s OncoEMR platform.
This pilot, launched with American Oncology Network and other community providers, lets clinicians at 1,600 cancer care locations order select Quest oncology tests inside their existing electronic health record workflows, with a broader...